IMPC phenotypes (gene matching)
- abnormal uterus morphology / IMPC
B6.Cg-Map3k8tm1.1Gkl/Flmg
| Status | Available to order |
| EMMA ID | EM:07150 |
| Citation information | RRID:IMSR_EM:07150 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6.Cg-Map3k8tm1.1Gkl/Flmg |
| Alternative name | Tpl2FL/FL [B6-Map3k8tm1.1Gkl/Flmg] |
| Strain type | Targeted Mutant Strains : Conditional mutation |
| Allele/Transgene symbol | Map3k8tm1.1Gkl |
| Gene/Transgene symbol | Map3k8 |
Information from provider
| Provider | George Kollias |
| Provider affiliation | Institute of Immunology, B.S.R.C. Al. Fleming |
| Genetic information | A 3-loxP targeting vector containing 5' and 3' homology arms with mouse Map3k8 (Tpl2) gene, a neomycin cassette flanked by loxP1 and loxP2 and exon 4 flanked by loxP2 and loxP3 was used for the generation of targeted mice through targeting of C57BL/6-derived Bruce4 ES cells with above vector and selection by homologous recombination. The final version of the mouse line derived from live mice bearing the homologous integration of targeting vector in the germ line where neomycin cassette was removed upon in vivo recombination by a C57BL/6 EIIa-cre strain. |
| Phenotypic information | This is a strain that can be used with tissue specific cre recombinase expressing strains to induce cre-mediated Tpl2 ablation. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | B.S.R.C. Alexander Fleming, Vari, Greece |
| Animals used for archiving | homozygous C57BL/6 males |
Disease and phenotype information
MGI phenotypes (gene matching)
- abnormal colon morphology / MGI
- abnormal dendritic cell antigen presentation / MGI
- decreased IgE level / MGI
- abnormal cytokine secretion / MGI
- rectal hemorrhage / MGI
- increased tumor growth/size / MGI
- increased incidence of tumors by chemical induction / MGI
- abnormal response to infection / MGI
- diarrhea / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- increased T cell proliferation / MGI
- immune system phenotype / MGI
- decreased IgG1 level / MGI
- increased IgG2a level / MGI
- abnormal tumor necrosis factor secretion / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-alpha secretion / MGI
- decreased interferon-beta secretion / MGI
- decreased interleukin-1 beta secretion / MGI
- increased interleukin-12b secretion / MGI
- decreased interleukin-6 secretion / MGI
- decreased susceptibility to endotoxin shock / MGI
- increased physiological sensitivity to xenobiotic / MGI
- abnormal enterocyte proliferation / MGI
- abnormal enterocyte apoptosis / MGI
- increased sensitivity to xenobiotic induced morbidity/mortality / MGI
- decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
- increased susceptibility to weight loss / MGI
- decreased macrophage cytokine production / MGI
- prenatal lethality, incomplete penetrance / MGI
- decreased colon length / MGI
Literature references
- Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.;Koliaraki Vasiliki, Roulis Manolis, Kollias George, ;2012;The Journal of clinical investigation;122;4231-42; 23064365